Orally administered glucans from the edible mushroomPleurotus pulmonariusreduce acute inflammation in dextran sulfate sodium-induced experimental colitis

Abstract

Polysaccharides are one of the most potent mushroom-derived substances exhibiting anti-inflammatory and immunomodulatory properties. The aims of the present study were to determine whether orally administered glucans from the edible mushroomPleurotus pulmonariuscould attenuate or prevent the development of experimental colitis in mice. Colonic inflammation was induced in mice by treatment with 3·5 % dextran sulfate sodium (DSS) for 18 d. Before or after DSS administration, mice were given hot water solubles (HWS) or mycelium extract (ME) (2 or 20 mg per mouse) daily in their food. Colonic damage was macroscopically and histologically evaluated. Inflammation was assessed by changes in colon length, TNF-α levels released by colonic samples in organ culture and myeloperoxidase (MPO) activity. mRNA levels of pro-inflammatory (IL-1β) and anti-inflammatory (IL-10) cytokines in colonic samples were determined by quantitative real-time RT-PCR.P. pulmonariusglucans attenuated and prevented the development of symptoms associated with DSS-induced colitis. High doses of HWS and ME blocked colon shortening, suppressed MPO activity and improved macroscopic score in all treatment groups. In addition, histological damage from colitis was reduced by HWS and ME at all doses. The tissue levels of TNF-α protein were significantly decreased and correlated with degree of inflammation and macroscopic score. All treatments significantly attenuated the increased DSS-mediated expression levels of IL-1β. We conclude that the different glucan preparations (HWS or ME) harvested fromP. pulmonariuswhen orally administered to DSS-treated mice attenuate the development of colonic inflammation, suggesting putative clinical utility for these extracts in the treatment of colitis.